Three Asian patients with plasma cell myeloma stage IIIa with IgG predominant were selected for autologous hematopoietic cell transplantation (HSCT). Total marrow irradiation (TMI) tomotherapy planned with melphalan 140 mg/m 2 as a preconditioning regimen of HSCT.
Introduction
Multiple myeloma is characterized by neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin. Potential complications Technology in Cancer Research & Treatment, Volume 8, Number 1, February 2009 include hypercalcemia, renal insufficiency, infection, and skeletal lesions. The diagnostic evaluation includes serum and urine protein electrophoresis with immunofixation, bone marrow biopsy and aspiration, and an evaluation for end-organ damage (complete blood count with differential and review of the peripheral smear, serum chemistries including calcium and creatinine, and an osteolytic bone survey). The following findings, if attributable to the underlying plasma cell disorder, are clear indications for treatment: anemia, hypercalcemia, renal insufficiency, lytic bone lesions or severe osteopenia, and extramedullary plasmacytomas (1) . The main treatment options for standard risk multiple myeloma are chemotherapy or autologous hematopoietic stem-cell transplantation (HSCT). Overall survival is markedly shortened for patients who experienced disease progression at 6 or 12 months.
Total body irradiation (TBI) has been widely used as part of an HSCT preparative regimen (2). The purpose of the preparative regimen is to help eradicate the patient's disease before infusing hematopoietic stem cells and to suppress the immune reaction. But long-term complications following TBI and HSCT from non-hematopoetic tissues receiving potentially unnecessary irradiation are common. In one study of 186 adults surviving at least one year (3), the most common complications included cataracts (15%) where surgery was necessary in (57%); Sicca syndrome (13%); hypothyroidism ( 6.5%); one-half required medical treatment; thyroiditis (3%) and asymptomatic alterations in pulmonary function (19%) (4).
Helical tomotherapy (HT) as a new CT-based rotational intensity modulated radiotherapy that can deliver highly conformal dose distributions (5, 6) . According to the properties of HT, total marrow irradiation (TMI) with HT was designed for conformal irradiation to the bone marrow. This approach has demonstrated the feasibility and potential dosimetric advantages of selectively delivering myeloablative doses of radiation to bone and marrow (7, 8) . The potential advantages, the acute toxicities, initial clinical experiences, and challenges of this approach were reported recently (9).
Here, we present the successful cases use of TMI treatment with 8 Gy to the bone and bone marrow spaces along the entire axis of a multiple myeloma in Asian patients as part of autologous hematopoietic cell transplantation regimen and compared the advantages and disadvantages between the plan of TBI and TMI.
Materials and Methods

Patient Characteristics
From August 2007 to October 2008, three patients of IgG, stage IIIa multiple myeloma (10) were enrolled. Patient 1: A 53-year-old woman with a history of hepatitis-C positive, heart failure syndrome, vascular heart disease with moderate tricuspid regurgitation, and degenerative joint disease visited our hospital because of lower back pain for one month. The compression fracture of T9-12 was seen on T-spine x-ray. Bone scan showed metastatic bone lesions at T spine and bilateral anterior ribs. Laboratory data revealed anemia (hemoglobin: 9.4 g/dl), negative urine Bence-Jones protein, reticulocyte count (1.2%), and hypergammaglobulinemia with κ-lights chain predominant (Ig G: 7,720 mg/dl). Bone marrow study had done and showed plasma cell myeloma. Then three courses of vincristineadriamycin-dexamethasone (VAD) and one course of dexamethasone/etoposide/cyclophosphamide/cisplatin (DECP) were prescribed. After these treatments, she received preauto HSCT evaluation and enrolled.
Patient 2: A 56-year-old male presented with a history of foamy urine with low back pain for two months. Laboratory data revealed normocytic anemia without leucopenia or thrombocytopenia, serum Protein electrophoresis (SPEP), and serum immunofixation study (IFE) showed IgG lamdalight chains predominant (10,900 mg/dl), negative urine Bence-Jones protein. Bone marrow study showed plasma cell myeloma. Then he received three courses of VAD and one course of DECP. After these treatments, he received pre-auto HSCT evaluation and enrolled.
Patient 3: A 56-year-old female was diagnosed as multiple myeloma, IgG lamda-light chains predominant (7,700 mg/ dl), stage IIIa at Chang-Gung hospital then she received thalidomide plus steroid therapy but she was not tolerable. Therefore, she visited our hospital for further help and she received three courses of VAD and one course of DECP. After these treatments, she received pre-auto HSCT evaluation and enrolled.
The Regimen of Autologous Stem Cell Transplantation in Multiple Myeloma
Eligibility criteria included symptomatic MM. Patients were excluded if they had the following: (i) stable stage I MM Durie-Salmon classification); (ii) severe abnormalities of cardiac, pulmonary, and hepatic functions; or (iii) serum creatinine level above 500 μM. All patients gave informed consent, and the study was approved by the institutional ethics committee of the Far Eastern Memorial Hospital.
The treatment protocol was modified from the Intergroupe Francophone du Mye´lome 9502 randomized trial and the conditioning regiment was replaced TBI to TMI (Fig. 1 ). The patients received three cycles of the VAD regimen. If they achieved partial response (the reduce rate of M-protein < 50%) then they received one course of DECP with G-CSF mobiliza-tion. Two weeks later, peripheral blood stem cells (PBSCs) were collected. Stem cells were collected after granulocyte colony-stimulating factor (G-CSF) priming (10 μg/kg/d for 6 days) in steady state. Daily apheresis was continued until at least 2 × 10 6 CD34 cells per kilogram were collected. No CD34 + selection was performed. Two weeks after PBSC collection, the evaluation of pre-HSCT for patient was done. If their cardiopulmonary, hepatic, and renal functions remained adequate, patient received TMI planning. If their cardiopulmonary, hepatic, and renal functions remained adequate, patient received TMI planning and the time form pre-HSCT evaluation to start TMI treatment spend around 4 weeks. Patient received TMI 8 Gy with helical tomotherapy technique delivered in 4 fractions over a 4-day period (days -6, -5, -4, -3) plus 140 mg/ m 2 intravenous melphalan (HDM140). HDM140 administered on day -2 by infusion over 30 minutes. PBSC transplantation was carried out on day 0. Hematopoietic growth factor support with granulocyte-CSF (G-CSF) was prescribed on day 5 after transplantation until granulocyte recovery (11). Toxicity of treatment was scored according to the Common Terminology Criteria for Adverse Events v3.0 (CTCAE v3.0).
The treatment response criteria were listed as below: complete response (CR) was defined as the absence of serum and urinary M-protein and no more than 5% plasma cells on bone marrow. Very good partial response (VGPR) was defined as 90% or greater decrease in bone marrow plasma cells and blood M-protein levels. Partial response (PR) was defined as 50% or greater decrease in blood and bone marrow findings. Stable disease was defined as less than 25% decrease in blood and bone marrow findings for a minimum of 3 months. Progression was defined as greater than 25% increase in Mprotein, greater than 25% increase in bone marrow plasma cells, or new bone lesions (9).
Helical Tomotherapy Planning
Immobilization: For patient 1, AccuFix™ Cantilever Board™ (WFR/Aquaplast Corp. and Q-Fix Systems, LLC, Wyckoff, New Jersey, USA) with thermoplastic fixation were used for head and shoulder immobilization. BlueBag™ immobilization system (Medical Intelligence, Schwabmünchen, Germany) was used to fix main trunk and extremities.
For the other patients, Type-S thermoplastics head frame (MT-CHFN-C, Civco MedTec, Kalona, Iowa, USA) with mold care cushion were used for head and shoulder immobilization. BlueBAG™ BodyFIX® total body cushion system (Medical Intelligence, Schwabmünchen, Germany) with cover sheet nestles around the patient's body parts and produces a uniform pressure using a vacuum. The entire immobilization device was used throughout the treatment sessions. Marks will be placed on the following sites: near the mouth on the head mask (about 20 cm from the top of the head), centrally in the chest region, mid thigh region (not lower than 125 cm from the top of the head, should be 5 cm below the hands), junction between the whole body and the lower extremities at 15 cm above knees. The center of the lower extremities should be marked at the center of the treatment length.
Computed Tomography (CT) Simulation:
The patients were planned with head first supine position for upper torso and with feet first supine position for lower extremities. The planning CT images were performed with dual source CT (Siemens SOMATOM Definition, Siemens Healthcare, Erlangen, Germany) where three sets of images were acquired during normal breathing, inspiration, and shallow expiration for upper torso. The normal breathing image set was used for planning calculation. The inspiration and expiration image sets (scan range from C4 to whole liver to cover lungs and liver, which took about 35 seconds scanning time) were fused to the planning images to contour the ribs, sternum, and spines to account for the motion. For the lower extremities, one set of CT images was acquired without using the cover sheet and vacuum pump. Because most critical organs are located in the central part of the body, two image sets were scanned with 2.5 mm and 5 mm for upper and lower part, respectively.
Contouring: All the CT images were sent to a Pinnacle 3 treatment planning system (Philips Healthcare, Madison, Wisconsin, USA) for contouring. The clinical target volume (CTV) included the entire skeletal system. The bone was contoured in the following regions: (a) skull bone, (b) scapula and clavicles, (c) sternum and thoracic ribs, (d) upper extremities, (e) spinal column from C1 to L5, (f) pelvic bone, and (g) lower extremities. Timothy et al. reported that they used a 5 mm margin for the arms and thighs. For all other bones, they used no margin because the GTV was the bone, but the biologic target was the marrow (12). According to the previous report and to prevent failure of treatment, we generated the margin for PTV with 0.8 cm for CTV extremities and with 0.5 cm margin for all other bones of CTV. For the ribs and sternum, there was no margin added as expiration and inspiration CT sets were used to determine the PTV sternum & rib . To overcome the uncertainty in the junction of the upper and lower part of planning, the upper PTV was delineated to the slice from the reference point back two slices. The lower PTV was targeted from the slice of the reference point in the lower image set. The upper PTV in the last targeting slice (from the slice of the reference point back two slices) and the lower PTV in the first slice (reference point) were given 100% of the dose. Then, the dose in the junction would be received 150% of the dose. The organs at risk (OARs) included the brain, optic nerves, lenses, eyes, parotid glands, oral cavity, thyroid gland, bilateral lungs, esophagus, heart, liver, spleen, pancreases, kidneys, bowel, bladder, and reproductive organs. After contouring the targets and critical organs, the images and structure set was sent to Tomotherapy Hi Art Planning Station (Tomotherapy, Inc., Madison, Wisconsin, USA).
Planning for TMI and TBI:
The prescription dose was 200 cGy per day (for 4 fractions) for a total dose of 800 cGy to the PTV. For planning objective, at least 95% volume of PTV was to receive 800 cGy and the mean dose of the OARs was reduced to 50% of the prescribed dose. The normal tissue dose constraints utilized were based on the clinical outcome of the target dose and dose limits to various OARs as mention before. The constraints on dose and penalty were adjusted accordingly during optimization. The field width, pitch, and modulation factor (MF) used for the treatment planning optimization were 2.5 cm, 0.32, and 3.0 for the upper torso and 5.0 cm, 0.4, and 2.0 for the lower extremities, respectively. The dose volume histograms (DVHs) were calculated for the target and individual OARs. Toxicity of treatment was scored according to the Common Terminology Criteria for Adverse Events v3.0 (CTCAE v3.0). In the meantime, the 8 Gy with 4 fractions of total body irradiation (TBI) plan was calculated by Philips ADAC Pinnacle 3 treatment planning system for comparing the TMI plan. The same CT images and contours from the tomotherapy plan were used in the TBI planning and using 6MV photon beams at distance of SSD 400 cm. In the calculation, inhomogeneity algorithms were applied. The dose to the lungs was using lung blocks of about one half-value thickness and the chest wall was supplemented with electron beams to mimic clinical situation of TBI.
Plan Scoring Index:
The conformal index (CI) and the homogeneity index (HI) had been used to evaluate the conformity and homogeneity of the plan. The conformal index (CI) for PTV Bone marrow were calculated using the formula CI = TV RI /TV, where TV RI was the target volume covered by the reference isodose and TV was the entire target volume (13). The homogeneity index (H-index) for PTV Bone marrow was defined as H-index = D Max /D Rx with D Max being the maximum dose in the PTV and D Rx being the prescription dose (14).
Image Guidance:
Daily check of patient positioning was performed by the MVCT system integrated in the tomotherapy machine. Briefly, before every treatment, MVCT scans were taken in selected regions using the normal mode (4 mm slice thickness) of the body and fused with the treatment planning CT scan using bony anatomy and soft tissue images such as the lungs. Image fusions were evaluated by the attending physician and physicist. The fusion can be verified for transverse, coronal, and sagittal views for each scan. Translational shifts and roll angles from the fusion results were used for setup corrections. To study the reproducibility of the setup process, post-treatment MVCT were performed.
For the first TMI patient, the MVCT scan was performed three times before the treatment session. Two MVCT scans that covered from orbits to T4 and T10 to the ischial tuberosities were performed to check the patient's whole body alignment. The other MVCT scan was performed for the lower extremities, which covered from 15 cm above knee to 15 cm below knee. The tolerance of setup error allowed only a 5 mm difference between the three scans in any of the three translation directions and 1º of difference in roll. Additional selected MVCT scans were performed after treatment to verify patient immobilization. For the second and third patient, the MVCT scan for the whole body performed from orbit to ischial tuberosities due to the operator station was upgraded to version 3.1. For the lower extremities, the scans covered from knees to ankles. To speed up the registration procedure for the whole body, the translational shifts from head and neck, chest, abdominal, and pelvic regions were recorded individually. The average shifts for the four regions were calculated and applied. The attending physician and physicist reviewed all the registration images after the average shifts and made the final necessary adjustments before the treatment.
Analysis
Descriptive statistics were collected for patients and disease characteristics, treatment features and toxicity. All analyses were performed using the Statistical Package for the Social Sciences, version 12.0 (SPSS, Chicago, IL, USA).
Results
Three patients were enrolled. The characteristics of patient were listed in Table I . Until to presentation, patient 1, 2 and 3 lived to 480, 115, and 66 days, respectively. All of three patients post transplant without evidence of active disease were noted. The response for patient 1 and 2 was VGPR (nearly CR). The response for patient 3 could not be clammed due to the interval of observation was less than 3 months. During TMI treatment, grade 1 vomiting was noted on patient 1, grade 1 nausea was noted on patient 2 and 3, and grade 1 anorexia were noted for all. The grade 1 mucositis was noted on the second day of TMI for patient 1 and grade 3 mucositis was noted 8 days after melphalan infusion for patient 1. Grade 2 diarrhea was noted 3 days after mephalan infusion for patient 2. Grade 2 nausea and vomiting was noted 4 days after mephalan infusion for patient 3.
The average for upper part and lower part of PT-V Bone marrow of CI and H-index were 1.50 ± 0.12 (range: 1.36 -1.59) and 1.40 ± 0.22 (range: 1.20 -1.65), 1.18 ± 0.02 (range: 1.15 -1.20), and 1.22 ± 0.11 (range: 1.11 -1.32), respectively. Isodose distributions to the target and OARs for one of three are shown in Figures 2A, B , and C. A comparison between TMI and TBI of the mean dose to the various organs is shown in Figures 3A, B , and C, respectively. The dose reduction of TMI tomotherapy to various OARs of head, chest and abdomen relative to TBI varied from 31% to 74% (average reduction rate: 54%), 21% to 51% (average reduction rate: 38.4%), and 46% to 63% (average reduction rate: 55.6%) (Table II) .
Mean value of registration for tomotherapy with pretreatment and post-treatment using kVCT-MVCT fusion are shown in Table III . The average treatment time for the upper versus lower part in beam-on time, setup time, and MVCT registration time took roughly 49.89 ± 2.29, 23.33 ± 2.88, and 11.66 ± 2.88 min versus 11.50 ± 0.95, 10.00 ± 0.00, and 7.33 ± 0.57 min, respectively.
Discussion
Three successful Asian patients of TMI treated with 8 Gy to the bone and bone marrow spaces along the entire axis of a multiple myeloma as part of autologous HSCT regimen. Until presentation, all of them were well without evidence of active disease after treatment and all received oral thalidomide for maintenance-therapy. During TMI tomotherapy, only grade 1 toxicities were noted for these patients. Comparing the average dose reduction to various OARs of head, chest, and abdomen between TMI tomotherapy and TBI were more than 54%, 38.4%, and 55.6%, respectively.
Different ethnicities might show a great diversity in treatment toxicities and effects. For example, epidermal growth factor receptor (EGFR) inhibitors are more effective in Asian patients than in patients of other ethnicities (15). Interstitial lung disease associated with the administration of gefitinib is also more common among Japanese patients than among patients of other ethnicities (16). Recently, Roswell Park Cancer Institute reported that race was one of factors significantly associated with grade 2 to 4 acute graft-versus-host disease (GVHD) after cyclophosphamide plus total-body irradiation as conditioning regiment of HSCT (RR = 1.54; P = 0.0003) (17). Up to day, the reports for using TMI technique with helical tomotherapy were noted in the Weston countries. Two for dosimetric analysis (7, 18), two for treatment experience sharing (8, 19) and one for dose escalation (9). Our results showed tomotherapy with TMI technique replaced TBI technique with 8 Gy as conditioning regiment for multiple myeloma could be acceptable for the Asian and the outcomes were feasible for the Asian, too.
Compared with conventional TBI regiment, TMI achieved was at least as effective results with less toxicity. Until to presentation, patient 1, 2, and 3 lived to 480, 115, and 66 days, respectively. All of three patients post transplant without evidence of active disease were noted. The response for patient 1 and 2 was VGPR (nearly CR). The response for patient 3 could not be clammed due to the interval of observation was less than 3 months. According to the previous reports, the new treatment techniques are at least as effective as TBI for the disease requiring the bone marrow transplantation and TMI technique reduced median organs dose form 30% to 88% (8, 19) . Recently, the clinical observation was reported by Wong et al. that the primarily grade 1-2 acute toxicities were noted in their study (9). Only grade 1 acute toxicities during TMI treatment were noted in our study that was similar with other reports (8, 9) . The grade 3 mucositis was noted 8 days after high-dose mephalan infusion for patient 1. Grade 2 diarrhea was noted 3 days after high-dose mephalan infusion for patient 2. Grade 2 nausea and vomiting was noted 4 days after high-dose mephalan infusion for patient 3. Toxicities of HDM include moderate nausea and vomiting, moderate to severe mucositis and diarrhea (20) . By successfully reducing dose accumulation in the oral cavity, esophagus, stomach, and small bowel (the average reduction rates which compared with 8 Gy TBI were 55%, 46%, 63%, and 60%, respectively), TMI in our study did not increase the toxicities obviously in the entire treatment regimen and as effective as TBI did.
TMI tomotherapy could achieve high conformity, and homogeneity without compromise of critical organs. The average for upper part versus lower part of PTV Bone marrow of CI and Hindex were 1.5 and 1.4 versus 1.2 and 1.2, respectively. The average dose reduction to various OARs was listed in Table  II . Compared with the dose reduction rate of OARs in the other studies about TMI versus TBI, 15-65% was reported by Wong et al. (9) and 30-88% was reported by Hui et al. (8) .
Our results showed the average reduction rate of OARs were 29-74% that was compatible with others.
To account for set-up variability and breathing motion, a planning target volume (PTV) was generated with a 0.5 cm margin for all other bones of CTV and 0.8 cm for CTV extremities , respectively. But in our experience, using 0.5 cm and 0.8 cm margin respectively for CTV and CTV extremities could achieve the similar result (8). It is helpful to use various sections of the body in MVCT scans for pretreatment patient setup simultaneously. We even repeated the MVCT scan after the treatment to monitor patient's moving condition during the long treatment procedure. The registration time for upper and lower part scanning with MVCT took 11.7 and 7.3 minutes, respectively. The maximum average value of registration for upper torso versus lower extremities in different translation directions were 5.1 mm versus 4.1 mm for pretreatment and 1.5 mm versus 0.7 mm for post-treatment, respectively (Table III) . This was well within our PTV margin design as mentioned before. Timothy et al. reported that they used a 5 mm margin for the arms and thighs. For all other bones, they used no margin (12). Hui et al. reported that they generated with a 1 cm margin around CTV (8). According to the correction data of registration either from pretreatment registration or from post-treatment confirmation in our study, we suggested that PTV was still needed for compensating the effects of organ and patient movement, and inaccuracies in beam and patient setup. The concerns about margin and danger were raised by several papers (21, 22) and the body motion in various regions of the body was not exactly the same. Therefore, seriously investigating the whole body motion in various regions of the body was needed in the future. Beside, the margin around CTV for PTV could be considerate lesser than 1 cm to reduce radiation dose in any healthy tissue if possible especially under well fixation and image-guided. Accordingly, developing special localizations to reduce mo- tion uncertainties and to increase the accuracy of the TMI treatment delivery was another important issue.
Because most critical organs are located in the central part of body, two image sets separated at the level of 15 cm above the knee were scanned with 2.5 mm and 5 mm for upper and lower part, respectively. Thus, this approach led to different weights in the upper and lower part. The mean values of registration for upper torso vs. lower extremities in vertical (mm), longitudinal (mm), and transverse (mm) direction were 3.1 vs. 4.1, 5.1 vs. 4.1, and 2.6 vs. 3.4 for pretreatment and 0.8 vs. 0.2, 1.5 vs. 0.7, 1.5 vs. 0.3 for post-treatment, respectively. In MVCT scanning, the field width is 4 mm.
Boswell et al. compared the registration results of MVCT against an independent, optically guided positioning system using a rigid head phantom (23). For bone and tissue registration algorithm, the uncertainty in y-direction with rotation displacement is 0.3 ± 0.6 mm (excluding outliers) and 1.8 ± 7.5 mm (including 24 registration results). The stabilization during treatment was reliable.
There are some limits to our study. First, because critical organ delicate delineation should be requested in the TMI planning as could as possible and treatment time should be as rapid as possible, we adapt two image scanning sets with 2.5 mm for upper part and 5 mm for lower part in TMI planning. This means we should consider the uncertainty in the junction of the upper and lower part of planning. Second, we didn't prescribe antiemetics on the first day of TMI tomotherapy for patient 1 and this led to nausea and vomiting in the patient. Although the dose delivery to abdomen organ is limited, we suggest prophylactic use of antiemetic. Third, the treatment is feasible and the results achieve VGPR but do not achieve CR. The small number case may be the one of reasons. The patients in our study received three courses of VAD only that differenced four courses of VAD in Intergroupe Francophone du Mye´lome 9502 randomized trial (11) that perhaps another one reason. However, according to the previous reports, the lower relapse probability is noted in the patients receiving the higher dose of total body irradiation (24, 25) . Therefore, the dose escalation with TMI technique for the Asian is warranted in the future.
Our results showed TMI technique replaced TBI technique with 8 Gy as conditioning regiment for multiple myeloma could be acceptable for the Asian and the outcomes were feasible for the Asians, too. The margin of PTV for TMI could be less than 1 cm under good fixation and close positioning confirmation with MVCT. Antiemetics should be prescribed in the whole course of TMI tomotherapy for emesis prevention.
